ArticleAntimicrobial agents and chemotherapy2022
Impact of
Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 53 citations in OpenAlex.
- Micafungin microevolution inVirulence · 2026Article
- Segmental duplications and supernumerary chromosomes drive antifungal drug resistance in Candida auris.Nature communications · 2026Article
- Evaluation of Sensititre YeastOne for antifungal susceptibility testing ofJournal of clinical microbiology · 2026Article
- Article
- Genomic landscape ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Deciphering the multidrug resistance paradigm inAntimicrobial agents and chemotherapy · 2026Review
- ER stress selects forFrontiers in microbiology · 2026Article
- Review
- The structural language of fungal cell wall sugars in WHO priority fungi: the determinant of pathogenicity and the gateway to new therapies.Frontiers in immunology · 2026Review
- A study of genomic complexity underlying multidrug resistance in Candida auris strains in Thailand.Scientific reports · 2025Article
- In Vivo Evolution of Candida auris Multidrug Resistance in a Patient Receiving Antifungal Treatment.The Journal of infectious diseases · 2025Article
- First Report ofJournal of fungi (Basel, Switzerland) · 2025Article
- A Candidozyma (Candida) auris-Optimized Episomal Plasmid-Induced Cas9-Editing System Reveals the Direct Impact of the S639F-Encoding FKS1 Mutation.The Journal of infectious diseases · 2025Article
- Evaluation of the MIC test strips for antifungal susceptibility testing ofJournal of clinical microbiology · 2025Article
- A benchmark dataset for validatingMicrobiology spectrum · 2025Article
- Tolerance and heteroresistance to echinocandins inmSphere · 2025Review
- Trends in Antifungal Resistance AmongJournal of fungi (Basel, Switzerland) · 2025Article
- Unveiling the hidden risk of caspofungin: insights from three adverse event reporting systems and network pharmacology integration.Frontiers in pharmacology · 2025Article
- Emergence of multidrug-resistantFrontiers in microbiology · 2025Article
- The multidrug-resistantCurrent research in microbial sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Echinocandins are frontline antifungal agents in the management of invasive infections due to multidrug resistant Candida auris. The study aimed to evaluate echinocandin resistance in C. auris isolates of multicentric origin, identify the resistance mechanism, and analyze the pharmacodynamic response to caspofungin in a neutropenic mouse model of infection. A total of 199 C. auris isolates originating from 30 centers across India were tested for susceptibility to echinocandins. Isolates with reduced susceptibility were evaluated for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.